428 patients was my guess, not 460. That is a very low number versus our original expectations for where they would be at this point. But on the bright side, Bloomberg says they added basically 10% to that total in a single month in September. So they do appear to be growing nicely off an unexpectedly low base, which gives some credence to JFM1330's argument for a long slow advance to 2,000 patients in the US. I hope that happens but I also know that the stock price will likely be more determined by the progress towards HIV NASH opportunity from here on. Cancer may well add to that in a couple of years and you never know if the companby will add new produccts also. Or maybe they will just gobbled up by another NASH player at some point.
Bucknelly21 wrote:460 patients roughly.... I know jfm articles are credible but that just seems so so low after almost a year and a half.